Quick News Spot

Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target


Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target

New York, New York--(Newsfile Corp. - October 20, 2025) - Emerging Growth Research today announced the initiation of coverage on OSR Holdings, Inc. (NASDAQ: OSRH) with a Buy-Emerging rating and a 12-month price target of $10.00, representing over 1,600% upside from the Company's recent closing price of $0.58.

The initiation report highlights OSR Holdings' innovative biotech portfolio, expanding 4th-party logistics (4PL) business, and pending acquisition of Woori IO, a noninvasive glucose monitoring company supported by Samsung Electronics. OSRH's diversified operations across cancer immunotherapy, biologics, and medical device distribution position it for significant growth and long-term value creation.

Key Highlights from the Initiation Report:

For a copy of the full initiation report, please visit:

https://emerginggrowth.com/wp-content/uploads/2025/10/FINAL-OSRH_Initiation_10.20.25.pdf

or

https://emerginggrowth.com/profile/osrh/ (on the right side of the page as you scroll down)

About OSR Holdings, Inc.

Founded in 2020 and headquartered in Bellevue, Washington and Gyeonggi-do, South Korea, OSR Holdings, Inc. (NASDAQ: OSRH) is a global healthcare company developing oral immunotherapies for cancer and biologics for degenerative diseases. The Company also distributes medical devices and systems through its RMC subsidiary and is expanding into 4PL logistics. OSRH's pending acquisition of Woori IO adds a breakthrough noninvasive glucose monitoring technology to its portfolio.

This press release contains forward-looking statements concerning business operations and financial performance as well as plans, objectives, and expectations for OSR Holdings, Inc. that are subject to risks and uncertainties. All statements other than statements of historical fact are forward-looking statements. These include but are not limited to statements regarding product development, regulatory milestones, market growth, and anticipated financial performance. Actual results could differ materially due to clinical, regulatory, financial, or competitive risks.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271104

Previous articleNext article

POPULAR CATEGORY

corporate

5594

entertainment

6803

research

3369

misc

6642

wellness

5601

athletics

7121